Episodios

  • Talking about cancer misinformation

    Talking about cancer misinformation
    May 22 2025
    If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you. 1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857 2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526
    Más Menos
    15 m
  • Four New Drugs

    Four New Drugs
    May 22 2025
    Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.
    Más Menos
    12 m
  • Mg to Prevent Cisplatin Kidney Injury

    Mg to Prevent Cisplatin Kidney Injury
    May 8 2025
    A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury. Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756 PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351 Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/
    Más Menos
    16 m
  • TI-CH, Updates on dostarlimab, ventoclax, & zongertinib

    TI-CH, Updates on dostarlimab, ventoclax, & zongertinib
    May 1 2025
    This episode summarizes recent updates on: Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)
    Más Menos
    12 m
  • BRCA Reversion Mutations

    BRCA Reversion Mutations
    Apr 24 2025
    BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors. Bibliography: 1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715 2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933 3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015
    Más Menos
    13 m
  • HOPA 25 Recap

    HOPA 25 Recap
    Apr 17 2025
    Recapping HOPA 25 and Portland *Great food (not discussed, the most excellent ETSU dinner at Arden) *COCOON *Pharmacists make everyone's job easier and keep patients out of the ED *A few more tidbits too!
    Más Menos
    12 m
  • Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview

    Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
    Apr 8 2025
    FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
    Más Menos
    12 m
  • Topotecan

    Topotecan
    Apr 3 2025
    A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)
    Más Menos
    10 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup